<code id='27D11C8135'></code><style id='27D11C8135'></style>
    • <acronym id='27D11C8135'></acronym>
      <center id='27D11C8135'><center id='27D11C8135'><tfoot id='27D11C8135'></tfoot></center><abbr id='27D11C8135'><dir id='27D11C8135'><tfoot id='27D11C8135'></tfoot><noframes id='27D11C8135'>

    • <optgroup id='27D11C8135'><strike id='27D11C8135'><sup id='27D11C8135'></sup></strike><code id='27D11C8135'></code></optgroup>
        1. <b id='27D11C8135'><label id='27D11C8135'><select id='27D11C8135'><dt id='27D11C8135'><span id='27D11C8135'></span></dt></select></label></b><u id='27D11C8135'></u>
          <i id='27D11C8135'><strike id='27D11C8135'><tt id='27D11C8135'><pre id='27D11C8135'></pre></tt></strike></i>

          leisure time

          leisure time

          author:focus    Page View:572
          Jeremey Wyatt ActiGraph

          As drugmakers wade into using digital health technologies, ActiGraph has made its mission to become the wearable of choice for the industry.

          The Pensacola, Fla.-based company creates  devices and software explicitly designed for clinical trials by focusing on features that matter to sponsors, like bulletproof reliability, access to raw sensor data, and 30-day battery life so that trial participants never have to worry about charging devices.

          advertisement

          There are many potential advantages to using wearables in clinical trials. Continuous data may collect a more comprehensive picture of how a patient responds to treatment and could help drugmakers complete trials faster with fewer participants. But risk-averse companies have been slow to adopt the technology and opt instead for the certainty of established methods for capturing data. The industry has yet to see a drug approved with evidence from a wearable device.

          Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

          GET STARTED Log In

          explore

          The cancer drug shortage isn’t new — and neither are the solutions
          The cancer drug shortage isn’t new — and neither are the solutions

          PreparingachemotherapytreatmentatDukeCancerCenterinDurham,N.C.GerryBroome/APAyounggirl,maybe5or6year

          read more
          Elon Musk says Twitter has 'negative cash flow' and 'heavy debt'
          Elon Musk says Twitter has 'negative cash flow' and 'heavy debt'

          0:53FILEPHOTO:ElonMusk,ChiefExecutiveOfficerofSpaceXandTeslaandownerofTwitter,gesturesasheattendsthe

          read more
          Anesthesiologist group: stop taking Ozempic before surgery
          Anesthesiologist group: stop taking Ozempic before surgery

          EspeciallyinthefirstweeksoftakingdrugslikeOzempic,foodstayslongerinthestomach—aprobleminsurgeries.Ad

          read more

          For Cytokinetics, FDA rejection of heart drug would help, not hinder

          MollyFerguson/STATCytokineticswasfounded26yearsagobuthasnotyetdevelopedadrugsuccessfullytoapproval.T